J Korean Med Sci.  2009 Aug;24(4):755-759. 10.3346/jkms.2009.24.4.755.

Disseminated Hemangioblastomatosis of the Central Nervous System without von Hippel-Lindau Disease: A Case Report

• Kim HR
• Suh YL
• Kim JW
• Lee JI

• KMID: 1779217
• DOI: http://doi.org/10.3346/jkms.2009.24.4.755

Abstract

We report a very rare case of hemangioblastomatosis that developed after surgical removal of a solitary cerebellar hemangioblastoma (HB). A 51-yr-old man presented with back pain 10 yr after undergoing surgery for cerebellar HB. Magnetic resonance imaging showed numerous mass lesions along the entire neuraxis accompanied by prominent leptomeningeal enhancement. Genomic DNA analysis showed no mutation in the von Hippel-Lindau (VHL) genes. A surgical specimen obtained from a lesion in the cauda equina showed pathological findings identical to those of the cerebellar HB that had been resected 10 yr earlier. External beam radiation therapy and radiosurgery were subsequently performed; however, the patient succumbed one year after receiving the diagnosis of hemangioblastomatosis. The reduction of tumor cell spillage during surgery and regular long-term follow-up are recommended for patients with HBs.

Keyword

Hemangioblastoma; von Hippel-Lindau Disease; Central Nervous System

MeSH Terms

Central Nervous System Neoplasms/*diagnosis/pathology/surgery
Cerebellar Neoplasms/pathology/radiotherapy/surgery
Hemangioblastoma/*diagnosis/pathology/surgery
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Recurrence
von Hippel-Lindau Disease/genetics

Figure

• 

  Fig. 1 Initial magnetic resonance images, pathology finding and postoperative MR images in first diagnosis. (A, B) Initial T1-weighted magnetic resonance images obtained after gadolinium infusion. Sagittal and axial images of the brain showing a well-enhanced cerebellar mass but no mass in the suprasellar or cervicovertebral junction. (C) Pathology microphotograph stained with hematoxylin and eosin (×400) showing large vacuolated stromal cells that have larger, hyperchromatic nuclei and an eosinophilic foamy cytoplasm. It is characterized by the accumulation of lipid droplets within stromal cells and a rich capillary network. (D) T1-weighted magnetic resonance images taken 1 yr after surgery. There was no evidence of residual or recurrent disease on MR images.

• 

  Fig. 2 Brain and lumbar magnetic resonance images and the pathology finding in disseminated recurrence. (A) T1-weighted magnetic resonance images obtained after gadolinium infusion. Sagittal view of the brain showing an enhancing mass in the suprasellar area with prominent leptomeningeal enhancement and another enhancing mass ventral to the upper spinal cord. (B) Sagittal view of the lumbar spine showing multiple enhancing nodules within the thoracolumbar spinal canal. (C) Histopathological photograph obtained from the mass in the cauda equina, which was stained with hematoxylin and eosin (×200). The architecture of tissue cells and morphology of the cells are identical with that of the cerebellar tumor shown in Fig. 1A.

Reference

1. Choyke PL, Filling-Katz MR, Shawker TH, Gorin MB, Travis WD, Chang R, Seizinger BR, Dwyer AJ, Linehan WM. von Hippel-Lindau disease: radiologic screening for visceral manifestations. Radiology. 1990. 174:815–820.

2. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology. 1995. 194:629–642.

3. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999. 340:1872–1879.

4. Glasker S, Bender BU, Apel TW, van Velthoven V, Mulligan LM, Zentner J, Neumann HP. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 2001. 70:644–648.

5. Neumann HP, Eggert HR, Weigel K, Friedburg H, Wiestler OD, Schollmeyer P. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg. 1989. 70:24–30.

6. Singounas EG. Haemangioblastomas of the central nervous system. Acta Neurochir (Wien). 1978. 44:107–113.

7. Lee JY, Dong SM, Park WS, Yoo NJ, Kim CS, Jang JJ, Chi JG, Zbar B, Lubensky IA, Linehan WM, Vortmeyer AO, Zhuang Z. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res. 1998. 58:504–508.

8. Richard S, David P, Marsot-Dupuch K, Giraud S, Beroud C, Resche F. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurg Rev. 2000. 23:1–22.

9. Niemela M, Lemeta S, Summanen P, Bohling T, Sainio M, Kere J, Poussa K, Sankila R, Haapasalo H, Kaariainen H, Pukkala E, Jaaskelainen J. Long-term prognosis of haemangioblastoma of the CNS: impact of von Hippel-Lindau disease. Acta Neurochir (Wien). 1999. 141:1147–1156.

10. Bakshi R, Mechtler LL, Patel MJ, Lindsay BD, Messinger S, Gibbons KJ. Spinal leptomeningeal hemangioblastomatosis in von Hippel-Lindau disease: magnetic resonance and pathological findings. J Neuroimaging. 1997. 7:242–244.

11. Mohan J, Brownell B, Oppenheimer DR. Malignant spread of haemangioblastoma: report on two cases. J Neurol Neurosurg Psychiatry. 1976. 39:515–525.

12. Reyns N, Assaker R, Louis E, Lejeune JP. Leptomeningeal hemangioblastomatosis in a case of von Hippel-Lindau disease: case report. Neurosurgery. 2003. 52:1212–1215.

13. Tohyama T, Kubo O, Kusano R, Miura N, Himuro H. A case of hemangioblastoma with subarachnoid dissemination. No Shinkei Geka. 1990. 18:83–88.

14. Weil RJ, Vortmeyer AO, Zhuang Z, Pack SD, Theodore N, Erickson RK, Oldfield EH. Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel-Lindau disease. Report of four cases. J Neurosurg. 2002. 96:775–787.

15. Kato M, Ohe N, Okumura A, Shinoda J, Nomura A, Shuin T, Sakai N. Hemangioblastomatosis of the central nervous system without von Hippel-Lindau disease: a case report. J Neurooncol. 2005. 72:267–270.

16. Hanse MC, Vincent A, van den Bent MJ. Hemangioblastomatosis in a patient with von Hippel-Lindau disease. J Neurooncol. 2007. 82:163–164.

17. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, Chauveau D, Balian A, Beigelman C, O'Toole D, Bernades P, Ruszniewski P, Richard S. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000. 119:1087–1095.

18. Hough DM, Stephens DH, Johnson CD, Binkovitz LA. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol. 1994. 162:1091–1094.

19. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. Lancet. 2003. 361:2059–2067.

20. Girmens JF, Erginay A, Massin P, Scigalla P, Gaudric A, Richard S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol. 2003. 136:194–196.

21. Niemela M, Maenpaa H, Salven P, Summanen P, Poussa K, Laatikainen L, Jaaskelainen J, Joensuu H. Interferon alpha-2a therapy in 18 hemangioblastomas. Clin Cancer Res. 2001. 7:510–516.